Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Aug;18(8):2509-2557.
doi: 10.1038/s41596-023-00843-6. Epub 2023 Jul 19.

Development of ionic liquid-coated PLGA nanoparticles for applications in intravenous drug delivery

Affiliations
Review

Development of ionic liquid-coated PLGA nanoparticles for applications in intravenous drug delivery

Christine M Hamadani et al. Nat Protoc. 2023 Aug.

Abstract

Polymeric nanoparticles (NPs) are a promising platform for medical applications in drug delivery. However, their use as drug carriers is limited by biological (e.g., immunological) barriers after intravenous administration. Ionic liquids (ILs), formed from bulky asymmetric cations and anions, have a wide variety of physical internal and external interfacing properties. When assembled on polymeric NPs as biomaterial coatings, these external-interfacing properties can be tuned to extend their circulation half-life when intravenously injected, as well as drive biodistribution to sites of interest for selective organ accumulation. In our work, we are particularly interested in optimizing IL coatings to enable red blood cell hitchhiking in whole blood. In this protocol, we describe the preparation and physicochemical and biological characterization of choline carboxylate IL-coated polymeric NPs. The procedure is divided into five stages: (1) synthesis and characterization of choline-based ILs (1 week); (2) bare poly(lactic-co-glycolic acid) (50:50, acid terminated) Resomer 504H (PLGA) NP assembly, modified from previously established protocols, with dye encapsulation (7 h); (3) modification of the bare particles with IL coating (3 h); (4) physicochemical characterization of both PLGA and IL-PLGA NPs by dynamic light scattering, 1H nuclear magnetic resonance spectroscopy, and transmission electron microscopy (1 week); (5) ex vivo evaluation of intravenous biocompatibility (including serum-protein resistance and hemolysis) and red blood cell hitchhiking in whole BALB/c mouse blood via fluorescence-activated cell sorting (1 week). With practice and technique refinement, this protocol is accessible to late-stage graduate students and early-stage postdoctoral scientists.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Lü, J. M. et al. Current advances in research and clinical applications of PLGA-based nanotechnology. Expert Rev. Mol. Diagn. 9, 325–341 (2009). - DOI - PubMed - PMC
    1. Park, J. et al. Enhancement of surface ligand display on PLGA nanoparticles with amphiphilic ligand conjugates. J. Control. Release 156, 109–115 (2011). - DOI - PubMed - PMC
    1. Manoochehri, S. et al. Surface modification of PLGA nanoparticles via human serum albumin conjugation for controlled delivery of docetaxel. Daru. https://doi.org/10.1186/2008-2231-21-58 (2013).
    1. Amo, L. et al. Surface functionalization of PLGA nanoparticles to increase transport across the BBB for Alzheimer’s disease. Appl. Sci. 11, 4305 (2021). - DOI
    1. Rezvantalab, S. et al. PLGA-based nanoparticles in cancer treatment. Front. Pharmacol. 9, 1260 (2018). - DOI - PubMed - PMC

Publication types

LinkOut - more resources